Ann: Bit225 Covid-19 Human Study Commenced, page-99

First 99 Last

Share
Profile

Follow
Michael Yoni

143 Posts.

12

15/09/22

10:52

Post #: 63712342
Share

Originally posted by nailsnglue: ↑

Antibody response in HIV-infected individuals tends to have half the antibody response to vaccines compared with other groups. The only other group which is is lower is organ transplant recipients who are on a range of anti-rejection drugs. You don't need to find all the same people for a study, just get a baseline and then daily antibodies and symptom score sheet. Those that are vaccinated will have perhaps higher IGg to start with but around 30% of HIV infected (vs 5% general population) individuals lose their IGg within 3 months of infection or vaccination. source. I still feel that with around .5 of the average population likely to contract or be exposed to COVID19 during six months we shall see some interesting data. It is said that immuno-compromised people have three times more chance of contracting severe COVID19 symptoms when exposed. So it is likely we do see some interesting data. This is all irrespective of ART-naive or not and is probably more related to individual CD4 levels. It will be difficult to put this into context in the study but not impossible.

We have a small study, yes, but we have no money and yet to spike interest from big money. This is a favourable step in the direction we want to take.

Expand

With respect to the immunocompromised .... in the article did they specifically say they are HIV pos or are they other immunocompromised conditions. They do have a * on the table....

BIT Price at posting: 5.7¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

MM1

Geochemical work at Newington picks up gold and copper anomalies for Midas

ASX Market Open: ASX200 to rise for Friday session | July 26

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

BGL

Bellevue aims for 45% production increase by FY 2028, announces $150M placement